ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market.Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
Palisade Bio, Inc. (PALI) stock surged +10.96%, trading at $0.71 on NASDAQ, up from the previous close of $0.64. The stock opened at $0.64, fluctuating between $0.63 and $0.74 in the recent session.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.
Employees | 8 |
Beta | 1.41 |
Sales or Revenue | $0.00 |
5Y Sales Change% | -0.962% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |